This educational activity is designed to incorporate evidence-based pathophysiology, diagnosis, and/or treatment of urologic disorders into clinical practice. Speakers will utilize their personal, institutional and evidence-based experience to address patient health care conditions requiring clinical and surgical treatment. Speakers will also utilize departmental quality improvement data, M&M data, and patient safety data to improve outcomes of urologic disease and other aspects of urologic patients’ general health. Evidence-based data regarding the changing aspects/newer approaches to surgical disease will be analyzed, and critical issues related to urology within the broader scope of American health care will be discussed. There are varying degrees to individuals’ knowledge regarding clinical and urologic treatments. While individuals may be aware of varied treatment within the urologists’ armamentarium it is beneficial to address the topics from an evidence-based approach.
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians
Designation of Credit Statement
The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity
Hours of Participation for Allied Health Professionals
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
- Urology Faculty
- Allied Healthcare Providers
- Community Physicians
At the conclusion of this activity, I will be able to:
- The participant will understand the role of prostate-specific antigen (PSA) testing as an aid to the early detection of prostate cancer
- The participant will be familiar with the randomized clinical trial data on PSA with respect to prostate cancer-specific mortality
- The participant will learn about current methods for more targeted PSA-based prostate cancer screening
Role in Meeting:
|William Catalona, MD|
|Ken Jacobsohn, MD||Planning Committee|
|William See, MD||Planning Committee|
All persons in control of content have no relevant financial relationships to disclose with the exception of the following person:
William Catalona, MD has disclosed that he has financial relationships as a consultant with Beckman Coulter, INc, DeCode Genetrics, Inc.
In accordance with the ACCME® Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved.
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.